Keyword: Sandoz

China's WuXi Biologics and Sinobioway will build biologics facilities; Takeda expects Velcade freefall and looks to offload R&D assets to cut costs.

Novartis CEO Vas Narasimhan conceded to investors today that the company does not yet have a good fix on how to ensure Sandoz's growth.

The combined value of those assets on the for-sale list, which include Novartis' U.S. generics dermatology business, could reach $2 billion.

Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.

India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.

Roche's Rituxan just got another break. Novartis says its knockoff version didn't pass muster at the FDA, likely lifting the U.S. biosim threat until 2019.

Novartis and Pear are partnering again, this time in a go-to-market deal for FDA-approved digital products to treat drug abuse.

Novartis’ prospects for launching a copy of GlaxoSmithKline’s Advair this year just went from highly unlikely to not happening.

Novartis investors' discontent with first-quarter results shows how much they're expecting of new CEO Vas Narasimhan.

Sandoz may have to wait a little longer for a clear shot at launching a biosimilar to Amgen's anti-inflammatory blockbuster Enbrel.